Tag: cutaneous T-cell lymphoma
Brentuximab Vedotin Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma...
The European Commission has extended the current conditional marketing authorization for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include the treatment of adult patients with...
FDA Approves Label Expansion for Brentuximab Vedotin
The approval of brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of adult patients with primary cutaneous anaplastic Large cell lymphoma or pcALC, which...
Seattle Genetics Submits Supplemental Biologics License Application Brentuximab Vedotin in Cutaneous...
Seattle Genetics has submitted a supplemental Biologics License Application or BLA to the U.S. Food and Drug Administration (FDA) for brentuximab vedotin (Adcetris®) for...
The Lancet Publishes Positive Phase III Trial Data of Brentuximab Vedotin...
Data from the randomized Phase III ALCANZA clinical trial evaluating brentuximab vedotin (Adcetris®) in patients with cutaneous T-cell lymphoma (CTCL) were published in the...
Alcanza Trial Demonstrates Highly Statistically Significant Improvement in Rate of Objective...
Results of the phase III Alcanza trial evaluating brentuximab vedotin (Adcetris®; Takeda Pharmaceutical and Seattle Genetics) in patients with cutaneous T-cell lymphoma (CTCL) shows...
Analysis of Phase III AETHERA Data Demonstrates Brentuximab Vedotin Consolidation Therapy...
Several new analysis of Phase III data from the AETHERA trial (NCT01100502) demonstrate that brentuximab vedotin (Adcetris®; Seattle Genetics) consolidation therapy significantly extends progression-free...
